Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Abstract

One Pediococcus acidilactici strain, named PA-GY2 was isolated from the gut of cultured Macrobrachium rosenbergii. In order to better examine the potential scope and applicability of this strain in M. rosenbergii culture, based on the control diet, four experimental diets containing single or combined immunostimulants were produced by supplementing with yeast (Saccharomyces cerevisiae, SC) or/and β-glucan (G), then fed to the prawns (6.70 g ± 0.74) in five groups, which were named as group C (control group), P (PA-GY2), PS (PA-GY2 + SC, 1:1), PG (PA-GY2 + G) and PGS (PA-GY2 + SC + G), respectively. After a 60-day feeding trial, growth performance, feed utilization, immune response and disease resistance of prawns were evaluated in the present study. Results indicated that (1) The growth performance of the prawns in group PS and PGS were significantly improved. The prawns in group PGS presented the lowest feed coefficiency (FC), while prawns in group C presented the highest FC. (2) The protease activity was significantly improved by dietary immunostimulants supplementation, meanwhile, prawns in the group PS presented the highest lipase activity. (3) The highest total hemocyte count and respiratory burst activity were found in the group P and PG, respectively. The phagocytic index of the prawns in the group C was significantly lower than those in group P and PGS. (4) Dietary PA-GY2 single or combined with SC or/and β-glucan increased the immune related genes expression, including some antibacterial and antioxidant enzymes, while decreased the tumor necrosis factor-α gene expression, which led to the decreased cumulative mortality rate of prawns during the Aeromonas hydrophila challenge test. Based on the results of growth performance, digestive enzymes activity and immune response of M. rosenbergii, PA-GY2 supplementation, single or combined with SC or/and β-glucan could be suggested as promising immunostimulants in prawns farming.

Keywords: Growth; Innate immunity response; Macrobrachium rosenbergii; Pediococcus acidilactici GY2; Saccharomyces cerevisiae; β-Glucan.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Pediococcus acidilacticiImproved Feed UtilizationBeneficial
Moderate
Pediococcus acidilacticiImproved Growth PerformanceBeneficial
Large
Pediococcus acidilacticiIncreased Immune-Related Gene ExpressionBeneficial
Moderate
Pediococcus acidilacticiIncreased Lipase ActivityBeneficial
Moderate
Pediococcus acidilacticiIncreased Phagocytic IndexBeneficial
Moderate
Pediococcus acidilacticiIncreased Protease ActivityBeneficial
Moderate
Pediococcus acidilacticiIncreased Respiratory Burst ActivityBeneficial
Moderate
Pediococcus acidilacticiIncreased Total Hemocyte CountsBeneficial
Moderate
Pediococcus acidilacticiReduced Mortality Rate During Pathogen ChallengeBeneficial
Large
Pediococcus acidilacticiReduced Tumor Necrosis Factor-α Gene ExpressionBeneficial
Moderate
Pediococcus acidilactici KABP™-021Improved Feed UtilizationBeneficial
Moderate
Pediococcus acidilactici KABP™-021Improved Phagocytic ActivityBeneficial
Moderate
Pediococcus acidilactici KABP™-021Increased Lipase ActivityBeneficial
Moderate
Pediococcus acidilactici KABP™-021Increased Protease ActivityBeneficial
Moderate
Pediococcus acidilactici KABP™-021Increased Respiratory Burst ActivityBeneficial
Moderate
Pediococcus acidilactici KABP™-021Increased Total Hemocyte CountsBeneficial
Moderate
Pediococcus acidilactici KABP™-021Reduced Cumulative Mortality RateBeneficial
Large
Pediococcus acidilactici KABP™-021Reduced Tumor Necrosis Factor-α Gene ExpressionBeneficial
Moderate
Pediococcus acidilactici MAK92P26AEnhanced Digestive Enzyme ActivityBeneficial
Large
Pediococcus acidilactici MAK92P26AIncreased Immune Gene ExpressionBeneficial
Large
Pediococcus acidilactici MAK92P26AReduced Cumulative MortalityBeneficial
Large
Pediococcus acidilactici R1001Improved Feed UtilizationBeneficial
Moderate
Pediococcus acidilactici R1001Improved Growth PerformanceBeneficial
Large
Pediococcus acidilactici R1001Improved Lipase ActivityBeneficial
Moderate
Pediococcus acidilactici R1001Improved Phagocytic ActivityBeneficial
Moderate
Pediococcus acidilactici R1001Increased Immune-Related Gene ExpressionBeneficial
Moderate
Pediococcus acidilactici R1001Increased Protease ActivityBeneficial
Moderate
Pediococcus acidilactici R1001Increased Respiratory Burst ActivityBeneficial
Moderate
Pediococcus acidilactici R1001Increased Total Hemocyte CountsBeneficial
Moderate
Pediococcus acidilactici R1001Reduced Mortality Rate During Pathogen ChallengeBeneficial
Large
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.